Summary

The global market for Dual Orexin Receptor Antagonist was estimated to be worth US$ 671 million in 2024 and is forecast to a readjusted size of US$ 1235 million by 2031 with a CAGR of 7.1% during the forecast period 2025-2031.
A Dual Orexin Receptor Antagonist(DORA)refers to a class of drugs that target both subtypes of orexin receptors,namely orexin receptor type 1(OX1R)and orexin receptor type 2(OX2R).DORAs are primarily developed as treatments for sleep disorders,particularly insomnia.
Currently, the market for Dual Orexin Receptor Antagonists is experiencing gradual acceptance. Pharmaceutical research institutions and clinical experts are increasingly focused on this class of drugs due to their unique mechanism of action and safety advantages in addressing sleep disturbances. At this stage, a diversified market environment is emerging, with both new entrants and approved products contributing to an atmosphere of innovation and evolving treatment concepts.
Future development trends are mainly reflected in advancements in drug design and the expansion of indications. As understanding of the underlying physiology of sleep disorders deepens, research teams are working on optimizing molecular structures to enhance both efficacy and safety. Moreover, there is potential for these agents to be applied beyond traditional insomnia treatment, possibly extending into the management of other neuropsychiatric conditions and fostering the development of personalized therapeutic strategies.
The driving forces behind market growth include the urgent demand for safe and effective treatment options, as well as continuous progress in scientific research and innovative drug development. At the same time, challenges such as stringent regulatory requirements, uncertainties in clinical data, and competition from other similar therapeutic agents pose obstacles. These forces and challenges together shape the current and future market landscape, necessitating a balanced approach between innovation and risk management.
This report aims to provide a comprehensive presentation of the global market for Dual Orexin Receptor Antagonist, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Dual Orexin Receptor Antagonist by region & country, by Type, and by Application.
The Dual Orexin Receptor Antagonist market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Dual Orexin Receptor Antagonist.
Market Segmentation
By Company
Merck
Eisal
Idorsia
Segment by Type
Suvorexant
Lemborexant
Daridorexant
Segment by Application
Hospital and Clinic
Retail Pharmacies
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Dual Orexin Receptor Antagonist manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Dual Orexin Receptor Antagonist in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Dual Orexin Receptor Antagonist in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

ページTOPに戻る

Table of Contents

1 Market Overview
1.1 Dual Orexin Receptor Antagonist Product Introduction
1.2 Global Dual Orexin Receptor Antagonist Market Size Forecast
1.2.1 Global Dual Orexin Receptor Antagonist Sales Value (2020-2031)
1.2.2 Global Dual Orexin Receptor Antagonist Sales Volume (2020-2031)
1.2.3 Global Dual Orexin Receptor Antagonist Sales Price (2020-2031)
1.3 Dual Orexin Receptor Antagonist Market Trends & Drivers
1.3.1 Dual Orexin Receptor Antagonist Industry Trends
1.3.2 Dual Orexin Receptor Antagonist Market Drivers & Opportunity
1.3.3 Dual Orexin Receptor Antagonist Market Challenges
1.3.4 Dual Orexin Receptor Antagonist Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Dual Orexin Receptor Antagonist Players Revenue Ranking (2024)
2.2 Global Dual Orexin Receptor Antagonist Revenue by Company (2020-2025)
2.3 Global Dual Orexin Receptor Antagonist Players Sales Volume Ranking (2024)
2.4 Global Dual Orexin Receptor Antagonist Sales Volume by Company Players (2020-2025)
2.5 Global Dual Orexin Receptor Antagonist Average Price by Company (2020-2025)
2.6 Key Manufacturers Dual Orexin Receptor Antagonist Manufacturing Base and Headquarters
2.7 Key Manufacturers Dual Orexin Receptor Antagonist Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Dual Orexin Receptor Antagonist
2.9 Dual Orexin Receptor Antagonist Market Competitive Analysis
2.9.1 Dual Orexin Receptor Antagonist Market Concentration Rate (2020-2025)
2.9.2 Global 5 and 10 Largest Manufacturers by Dual Orexin Receptor Antagonist Revenue in 2024
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Dual Orexin Receptor Antagonist as of 2024)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Suvorexant
3.1.2 Lemborexant
3.1.3 Daridorexant
3.2 Global Dual Orexin Receptor Antagonist Sales Value by Type
3.2.1 Global Dual Orexin Receptor Antagonist Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Dual Orexin Receptor Antagonist Sales Value, by Type (2020-2031)
3.2.3 Global Dual Orexin Receptor Antagonist Sales Value, by Type (%) (2020-2031)
3.3 Global Dual Orexin Receptor Antagonist Sales Volume by Type
3.3.1 Global Dual Orexin Receptor Antagonist Sales Volume by Type (2020 VS 2024 VS 2031)
3.3.2 Global Dual Orexin Receptor Antagonist Sales Volume, by Type (2020-2031)
3.3.3 Global Dual Orexin Receptor Antagonist Sales Volume, by Type (%) (2020-2031)
3.4 Global Dual Orexin Receptor Antagonist Average Price by Type (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital and Clinic
4.1.2 Retail Pharmacies
4.1.3 Other
4.2 Global Dual Orexin Receptor Antagonist Sales Value by Application
4.2.1 Global Dual Orexin Receptor Antagonist Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Dual Orexin Receptor Antagonist Sales Value, by Application (2020-2031)
4.2.3 Global Dual Orexin Receptor Antagonist Sales Value, by Application (%) (2020-2031)
4.3 Global Dual Orexin Receptor Antagonist Sales Volume by Application
4.3.1 Global Dual Orexin Receptor Antagonist Sales Volume by Application (2020 VS 2024 VS 2031)
4.3.2 Global Dual Orexin Receptor Antagonist Sales Volume, by Application (2020-2031)
4.3.3 Global Dual Orexin Receptor Antagonist Sales Volume, by Application (%) (2020-2031)
4.4 Global Dual Orexin Receptor Antagonist Average Price by Application (2020-2031)
5 Segmentation by Region
5.1 Global Dual Orexin Receptor Antagonist Sales Value by Region
5.1.1 Global Dual Orexin Receptor Antagonist Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Dual Orexin Receptor Antagonist Sales Value by Region (2020-2025)
5.1.3 Global Dual Orexin Receptor Antagonist Sales Value by Region (2026-2031)
5.1.4 Global Dual Orexin Receptor Antagonist Sales Value by Region (%), (2020-2031)
5.2 Global Dual Orexin Receptor Antagonist Sales Volume by Region
5.2.1 Global Dual Orexin Receptor Antagonist Sales Volume by Region: 2020 VS 2024 VS 2031
5.2.2 Global Dual Orexin Receptor Antagonist Sales Volume by Region (2020-2025)
5.2.3 Global Dual Orexin Receptor Antagonist Sales Volume by Region (2026-2031)
5.2.4 Global Dual Orexin Receptor Antagonist Sales Volume by Region (%), (2020-2031)
5.3 Global Dual Orexin Receptor Antagonist Average Price by Region (2020-2031)
5.4 North America
5.4.1 North America Dual Orexin Receptor Antagonist Sales Value, 2020-2031
5.4.2 North America Dual Orexin Receptor Antagonist Sales Value by Country (%), 2024 VS 2031
5.5 Europe
5.5.1 Europe Dual Orexin Receptor Antagonist Sales Value, 2020-2031
5.5.2 Europe Dual Orexin Receptor Antagonist Sales Value by Country (%), 2024 VS 2031
5.6 Asia Pacific
5.6.1 Asia Pacific Dual Orexin Receptor Antagonist Sales Value, 2020-2031
5.6.2 Asia Pacific Dual Orexin Receptor Antagonist Sales Value by Region (%), 2024 VS 2031
5.7 South America
5.7.1 South America Dual Orexin Receptor Antagonist Sales Value, 2020-2031
5.7.2 South America Dual Orexin Receptor Antagonist Sales Value by Country (%), 2024 VS 2031
5.8 Middle East & Africa
5.8.1 Middle East & Africa Dual Orexin Receptor Antagonist Sales Value, 2020-2031
5.8.2 Middle East & Africa Dual Orexin Receptor Antagonist Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Dual Orexin Receptor Antagonist Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Dual Orexin Receptor Antagonist Sales Value and Sales Volume
6.2.1 Key Countries/Regions Dual Orexin Receptor Antagonist Sales Value, 2020-2031
6.2.2 Key Countries/Regions Dual Orexin Receptor Antagonist Sales Volume, 2020-2031
6.3 United States
6.3.1 United States Dual Orexin Receptor Antagonist Sales Value, 2020-2031
6.3.2 United States Dual Orexin Receptor Antagonist Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Dual Orexin Receptor Antagonist Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Dual Orexin Receptor Antagonist Sales Value, 2020-2031
6.4.2 Europe Dual Orexin Receptor Antagonist Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Dual Orexin Receptor Antagonist Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Dual Orexin Receptor Antagonist Sales Value, 2020-2031
6.5.2 China Dual Orexin Receptor Antagonist Sales Value by Type (%), 2024 VS 2031
6.5.3 China Dual Orexin Receptor Antagonist Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Dual Orexin Receptor Antagonist Sales Value, 2020-2031
6.6.2 Japan Dual Orexin Receptor Antagonist Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Dual Orexin Receptor Antagonist Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Dual Orexin Receptor Antagonist Sales Value, 2020-2031
6.7.2 South Korea Dual Orexin Receptor Antagonist Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Dual Orexin Receptor Antagonist Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Dual Orexin Receptor Antagonist Sales Value, 2020-2031
6.8.2 Southeast Asia Dual Orexin Receptor Antagonist Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Dual Orexin Receptor Antagonist Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Dual Orexin Receptor Antagonist Sales Value, 2020-2031
6.9.2 India Dual Orexin Receptor Antagonist Sales Value by Type (%), 2024 VS 2031
6.9.3 India Dual Orexin Receptor Antagonist Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Merck
7.1.1 Merck Company Information
7.1.2 Merck Introduction and Business Overview
7.1.3 Merck Dual Orexin Receptor Antagonist Sales, Revenue, Price and Gross Margin (2020-2025)
7.1.4 Merck Dual Orexin Receptor Antagonist Product Offerings
7.1.5 Merck Recent Development
7.2 Eisal
7.2.1 Eisal Company Information
7.2.2 Eisal Introduction and Business Overview
7.2.3 Eisal Dual Orexin Receptor Antagonist Sales, Revenue, Price and Gross Margin (2020-2025)
7.2.4 Eisal Dual Orexin Receptor Antagonist Product Offerings
7.2.5 Eisal Recent Development
7.3 Idorsia
7.3.1 Idorsia Company Information
7.3.2 Idorsia Introduction and Business Overview
7.3.3 Idorsia Dual Orexin Receptor Antagonist Sales, Revenue, Price and Gross Margin (2020-2025)
7.3.4 Idorsia Dual Orexin Receptor Antagonist Product Offerings
7.3.5 Idorsia Recent Development
8 Industry Chain Analysis
8.1 Dual Orexin Receptor Antagonist Industrial Chain
8.2 Dual Orexin Receptor Antagonist Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Dual Orexin Receptor Antagonist Sales Model
8.5.2 Sales Channel
8.5.3 Dual Orexin Receptor Antagonist Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer